MIAMI, May 02, 2024 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will report first quarter 2024 financial results and provide a business update on Tuesday, May 14, 2024 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 5:00 p.m. ET.
| Conference Call Details: | |||
| Conference Call Number: | 1.877.407.0789 | ||
| Conference ID: | 13745868 | ||
| Call meTM Feature: | Click Here | ||
| Webcast: | Click Here | ||
An archived replay of the webcast will be available on the “Events & Presentations” section of the Company’s website following the conference.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.
Investor Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
Sober.Buzz the Sober Token spreading the good $BUZZ! Sober.Buzz is the cryptocurrency being developed by…
Partners with Company Management and Thoma Bravo to Support NextGen Healthcare’s Growth CHICAGO & SAN…
The company will showcase innovations designed to optimize the oncology care workflow and enable improved…
Investment positions SETWorks for accelerated innovation and expanded impact in disability services KANSAS CITY, Mo.,…
BRAINTREE, Mass. and NEW YORK, May 2, 2025 /PRNewswire/ -- MIB, the life insurance industry's most…
Delivered on Quarterly Revenue and EBITDA Guidance Reiterate full year Revenue and Adjusted EBITDA guidance…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="1px" width="1px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
